Go to main content
Tricals - The highway towards a cure
Leuven Center for ALS (LEUCALS)

UZ Leuven

Belgium - Leuven

The Leuven Center for ALS is a reference center for ALS in Belgium, which combines clinical care for patients with research into disease causes, disease mechanisms and new biomarkers and treatments for ALS.

In the Leuven Center for ALS 120-130 new patients with ALS are seen annually and about 250 patients are followed up in by the local multidisciplinary care team. The center is actively involved in basic and clinical ALS research. Our clinical research activities include genetic, imaging (including PET/MRI imaging), electrophysiological and biomarker studies, as well as phase I-III clinical trials. Our basic research focuses on the generation of patient-derived stem cell models for ALS and FTD to study disease mechanisms. We also use these models to identify and validate molecular targets for new treatments.

Specialists in this centre

Philip van Damme

Professor of Neurology

Ann D’hondt

Study coordinator

Lien Beullens

Study coordinator

Laura De Velder

Study coordinator

Evi Parente

Study coordinator

Petra Tilkin

Study coordinator

Fouke Ombelet

Nurse consulent & postdoc

Joke De Vocht

Clinical (neuro)psychologist & postdoc

Frederik Hobin

PhD student

Nikita Lamaire

Study coordinator & nurse consultant

Current trials in this centre

Open for participation

MAGNET lithium trial

Phase 3
IIT
UNC13A

The MAGNET lithium trial studies the efficacy of lithium carbonate in ALS patients positive for the homozygous UNC13A mutation.

More about this trial

Open for participation

reALiSe

Phase 2
Industry
No

In the reALiSe study the safety and efficacy of the drug ARGX-119 for the treatment of ALS is investigated.

More about this trial

Closed for participation

DAZALS

Phase 2
Industry
No

In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS.

More about this trial

Closed for participation

VRG50635 trial

Phase 1
Industry
No

Verge Genomics is conducting a phase 1b trial to evaluate the safety, tolerability, and potential efficacy of VRG50635.

More about this trial

Closed for participation

FUSION

Phase 3
Industry
FUS

This study investigates the safety & efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene.

More about this trial

Archived

TUDCA-ALS

Phase 3
IIT
No

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

More about this trial

Archived

PHOENIX

Phase 3
Industry
No

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035'.

More about this trial

Archived

CardinALS

Phase 2
Industry
No

The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms.

More about this trial

Archived

ADORE

Phase 3
Industry
No

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of FNP122 for people with ALS.

More about this trial

Archived

VALOR

Phase 3
Industry
SOD1

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with ALS.

More about this trial

Archived

APL2-ALS-206 trial

Phase 2
Industry
No

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS.

More about this trial

Archived

COURAGE-ALS

Phase 3
Industry
No

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS.

More about this trial

Contact this centre

If you would like to contact us or register for a trial, leave your details here.